Efficacy and safety of simeprevir with PegIFN/ribavirin in naïve or experienced patients infected with chronic HCV genotype 4

Journal of Hepatology

Volumn 62, Issue 5, 2015, Pages 1047-1055

  Moreno, Christophe ^a   Hezode, Christophe ^b   Marcellin, Patrick ^c   Bourgeois, Stefan ^d   Francque, Sven ^e   Samuel, Didier ^f   Zoulim, Fabien ^g   Grange, Jean Didier ^h   Shukla, Umesh ⁱ   Lenz, Oliver ^j   Ouwerkerk Mahadevan, Sivi ^k   Fevery, Bart ^j   Peeters, Monika ^j   Beumont, Maria ^j   Jessner, Wolfgang ^j  

^a ERASME HOSPITAL   (Belgium)

^b UNIVERSITÉ PARIS EST CRÉTEIL   (France)

^c BEAUJON HOSPITAL   (France)

^d ZNA Campus Stuivenberg ^*  (Belgium)

^e ANTWERP UNIVERSITY HOSPITAL   (Belgium)

^f HÔPITAL PAUL BROUSSE   (France)

^g CROIX ROUSSE HOSPITAL   (France)

^h HÔPITAL TENON   (France)

ⁱ JANSSEN RESEARCH AND DEVELOPMENT   (United States)

^j JANSSEN RESEARCH FOUNDATION   (Belgium)

^k JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

more..

Author keywords

[No Author keywords available]

Indexed keywords

DIAZEPAM; METHADONE; PEGINTERFERON ALPHA2A; RIBAVIRIN; SIMEPREVIR; VIRUS RNA; ALPHA INTERFERON; ANTIVIRUS AGENT; MACROGOL DERIVATIVE; RECOMBINANT PROTEIN;

ADULT; AGED; ANEMIA; ARTICLE; ASTHENIA; BRADYCARDIA; CONTROLLED STUDY; DRUG EFFICACY; DRUG INTOXICATION; DRUG SAFETY; DRUG TREATMENT FAILURE; DYSPNEA; FATIGUE; FEMALE; FLU LIKE SYNDROME; HEPATITIS C; HEPATITIS C VIRUS GENOTYPE 4; HUMAN; HUMAN TISSUE; HYPOGLYCEMIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NEUTROPENIA; OPEN STUDY; OUTCOME ASSESSMENT; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PRURITUS; RASH; RELAPSE; SUSTAINED VIROLOGIC RESPONSE; TREATMENT RESPONSE; CLINICAL TRIAL; COMBINATION DRUG THERAPY; DRUG ADMINISTRATION; DRUG EFFECTS; ETHNOLOGY; GENETICS; HEPACIVIRUS; HEPATITIS C, CHRONIC; MIDDLE AGED; PROCEDURES; SECONDARY PREVENTION; TREATMENT OUTCOME; VIROLOGY; VIRUS LOAD;

ANTIVIRAL AGENTS; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; RECOMBINANT PROTEINS; RIBAVIRIN; RNA, VIRAL; SECONDARY PREVENTION; SIMEPREVIR; TREATMENT OUTCOME; VIRAL LOAD;

EID: 84925619517     PISSN: 01688278     EISSN: 16000641     Source Type: Journal    
DOI: 10.1016/j.jhep.2014.12.031     Document Type: Article

References (33)

1. S.M. Kamal, and I.A. Nasser Hepatitis C genotype 4: what we know and what we don't yet know Hepatology 47 2008 1371 1383
2. C. Cifuentes, J.A. Mira, J. Vargas, K. Neukam, C. Escassi, and S. García-Rey Prevalence of hepatitis virus infection markers in HIV-infected patients in Southern Spain Enferm Infecc Microbiol Clin 30 2012 452 457
3. F. Nicot, F. Legrand-Abravanel, K. Sandres-Saune, A. Boulestin, M. Dubois, and L. Alric Heterogeneity of hepatitis C virus genotype 4 strains circulating in south-western France J Gen Virol 86 2005 107 114
4. S.M. Kamal Hepatitis C genotype 4 therapy: increasing options and improving outcomes Liver Int 29 Suppl 1 2009 39 48
5. M.A. Khattab, P. Ferenci, S.J. Hadziyannis, M. Colombo, M.P. Manns, and P.L. Almasio Management of hepatitis C virus genotype 4: recommendations of an international expert panel J Hepatol 54 2011 1250 1262
6. American Association for the Study of Liver Diseases (AASLD). Recommendations for testing, managing, and treating hepatitis C. Available from: < www.hcvguidelines.org/full-report-view >; 2014 [accessed 8.07.14].
7. European Association for the Study of the Liver. EASL Recommendations on treatment of hepatitis C 2014. Available from: < http://www.easl.eu/-newsroom/latest-news/easl-recommendations-on-treatment-of-hepatitis-c-2014 >; 2014 [accessed 8.07.14].
8. O. Lenz, L. Vijgen, J.M. Berke, M.D. Cummings, B. Fevery, and M. Peeters Virologic response and characterisation of HCV genotype 2-6 in patients receiving TMC435 monotherapy (study TMC435-C202) J Hepatol 58 2013 445 451
9. C. Moreno, T. Berg, T. Tanwandee, S. Thongsawat, H. Van Vlierberghe, and S. Zeuzem Antiviral activity of TMC435 monotherapy in patients infected with HCV genotypes 2-6: TMC435-C202, a phase IIa, open-label study J Hepatol 56 2012 1247 1253
10. H.W. Reesink, G.C. Fanning, K.A. Farha, C. Weegink, A. Van Vliet, and G. van 't Klooster Rapid HCV-RNA decline with once daily TMC435: a phase I study in healthy volunteers and hepatitis C patients Gastroenterology 138 2010 913 921
11. Manns M, Reesink H, Moreno C, Berg T, Benhamou Y, Horsmans Y, et al. OPERA-1 trial (study TMC435-C201): interim analysis of safety and antiviral activity of TMC435 in treatment-naive genotype 1 HCV patients. Abstract in: 44th annual meeting of the European Association for the Study of the Liver (EASL), Copenhagen, Denmark, 22-26 April, 2009.
12. I.M. Jacobson, G.J. Dore, G.R. Foster, M.W. Fried, M. Radu, and V.V. Rafalsky Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial Lancet 384 2014 403 413
13. M. Manns, P. Marcellin, F. Poordad, E.S. de Araujo, M. Buti, and Y. Horsmans Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-blind, placebo-controlled phase 3 trial Lancet 384 2014 414 426
14. S. Zeuzem, T. Berg, E. Gane, P. Ferenci, G.R. Foster, and M.W. Fried Simeprevir increases rate of sustained virologic response among treatment-experienced patients with HCV genotype-1 infection: a Phase IIb trial Gastroenterology 146 2014 430 441
15. Hinrichsen H, Reddy KR, Zoulim F, Weiland O, Horban A, Taliani G, et al. Simeprevir versus telaprevir in combination with pegylated interferon and ribavirin in HCV genotype 1-infected patients: the phase III ATTAIN study. Abstract in: viral hepatitis congress 2014, 2014.
16. X. Forns, E. Lawitz, S. Zeuzem, E. Gane, J.P. Bronowicki, and P. Andreone Simeprevir with peginterferon and ribavirin leads to high rates of SVR in patients with HCV genotype 1 who relapsed after previous therapy: a phase 3 trial Gastroenterology 146 2014 1669 1679
17. E. Lawitz, A. Mangia, D. Wyles, M. Rodriguez-Torres, T. Hassanein, and S.C. Gordon Sofosbuvir for previously untreated chronic hepatitis C infection N Engl J Med 368 2013 1878 1887
18. K.R. Reddy, S. Zeuzem, and F. Zoulim A Phase III randomised, double-blind study to evaluate the efficacy, safety and tolerability of simeprevir versus telaprevir in combination with pegylated interferon and ribavirin in chronic hepatitis C virus genotype 1 treatment-experienced patients: the ATTAIN study Hepatol Int 8 Suppl 1 2014 1 405
19. T. Poynard, M. Colombo, J. Bruix, E. Schiff, R. Terg, and S. Flamm Peginterferon alfa-2b and ribavirin: effective in patients with hepatitis C who failed interferon alfa/ribavirin therapy Gastroenterology 136 2009 1618 1628
20. Medivir AB. Simeprevir approved in the European Union for the treatment of adults with hepatitis C genotype 1 and 4 infection. Available from: < http://news.cision.com/medivir/r/simeprevir-approved-in-the-european-union-for-the-treatment-of-adults-with-hepatitis-c-genotype-1-an,c9586720 >;2014 [accessed 27.10.14].
21. G. Esmat, M. El Raziky, M. El Kassas, M. Hassany, and M.E. Gamil The future for the treatment of genotype 4 chronic hepatitis C Liver Int 32 Suppl 1 2012 146 150
22. F. Hasan, H. Asker, J. Al-Khaldi, I. Siddique, M. Al-Ajmi, and S. Owaid Peginterferon alfa-2b plus ribavirin for the treatment of chronic hepatitis C genotype 4 Am J Gastroenterol 99 2004 1733 1737
23. J.J. Urquijo, M. Diago, J. Boadas, R. Planas, R. Solá, and J.A. Del Olmo Safety and efficacy of treatment with pegylated interferon alpha-2a with ribavirin in chronic hepatitis C genotype 4 Ann Hepatol 12 2013 30 35
24. S.M. Kamal, A.A. El Tawil, T. Nakano, Q. He, J. Rasenack, and S.A. Hakam Peginterferon {alpha}-2b and ribavirin therapy in chronic hepatitis C genotype 4: impact of treatment duration and viral kinetics on sustained virological response Gut 54 2005 858 866
25. S.M. Kamal, S.S. El Kamary, M.D. Shardell, M. Hashem, I.N. Ahmed, and M. Muhammadi Pegylated interferon alpha-2b plus ribavirin in patients with genotype 4 chronic hepatitis C: the role of rapid and early virologic response Hepatology 46 2007 1732 1740
26. B. Fevery, T. Verbinnen, M. Peeters, M. Zucchetto, J. Witek, and W. Jessner Virology analyses of HCV isolates from genotype 4 patients treated with simeprevir in combination with peginterferon/ribavirin in the Phase III RESTORE study Hepatology 60 2014 92A abs 1789
27. T. Asselah, S. De Muynck, P. Broët, J. Masliah-Planchon, M. Blanluet, and I. Bièche IL28B polymorphism is associated with treatment response in patients with genotype 4 chronic hepatitis C J Hepatol 56 2012 527 532
28. M. Manns, H. Reesink, T. Berg, G. Dusheiko, R. Flisiak, and P. Marcellin Rapid viral response of once-daily TMC435 plus pegylated interferon/ribavirin in hepatitis C genotype-1 patients: a randomized trial Antivir Ther 16 7 2011 1021 1033
29. H.I. Al Ashgar, M.Q. Khan, M. Al-Ahdal, T.S. Al, A.S. Helmy, and Q.A. Al Hepatitis C genotype 4: genotypic diversity, epidemiological profile, and clinical relevance of subtypes in Saudi Arabia Saudi J Gastroenterol 19 2013 28 33
30. C.M. Lange, C. Sarrazin, and S. Zeuzem Review article: specifically targeted anti-viral therapy for hepatitis C - A new era in therapy Aliment Pharmacol Ther 32 2010 14 28
31. R. Kapoor, A. Kohli, S. Sidharthan, Z. Sims, T.L. Petersen, and A. Osinusi All oral treatment for genotype 4 chronic hepatitis C infection with sofosbuvir and ledipasvir: interim results from the NIAID SYNERGY trial Hepatology 60 2014 317A abs 240
32. P. Andreone, M.G. Colombo, J.V. Enejosa, I. Koksal, P. Ferenci, and A. Maieron ABT-450, ritonavir, ombitasvir, and dasabuvir achieves 97% and 100% sustained virologic response with or without ribavirin in treatment-experienced patients with HCV genotype 1b infection Gastroenterology 147 2014 359 365
33. A.S. Lok, D.F. Gardiner, C. Hezode, E.J. Lawitz, M. Bourliere, and G.T. Everson Randomized trial of daclatasvir and asunaprevir with or without PegIFN/RBV for hepatitis C virus genotype 1 null responders J Hepatol 60 2014 490 499